On the other hand, multivariate analysis using Cox proportional hazards regression analysis using RIP2 expression and clinical features (triple-negative status, axillary lymph node involvement, ER status, size, and age) indicated that RIP2 is an independent prognostic biomarker (P = 0.0033, HR 1.43, 95% CI 1.10, 1.77) in addition to tumor size greater than 2cm (P <0.0001, HR 1.97, 95% CI 1.65, 2.29) (multivariate analysis with and without RIP2 expression in Figure 2A and B, respectively). This evidence concerns the gene RIPK2 and neoplasm.